- Home
- DAVE vs TLX Comparison
DAVE vs TLX Comparison
Compare DAVE & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVE
- TLX
- Stock Information
- Founded
- DAVE 2017
- TLX 2015
- Country
- DAVE United States
- TLX Australia
- Employees
- DAVE N/A
- TLX N/A
- Industry
- DAVE Retail: Computer Software & Peripheral Equipment
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- DAVE Technology
- TLX Health Care
- Exchange
- DAVE Nasdaq
- TLX Nasdaq
- Market Cap
- DAVE 3.2B
- TLX 3.6B
- IPO Year
- DAVE N/A
- TLX N/A
- Fundamental
- Price
- DAVE $251.02
- TLX $10.80
- Analyst Decision
- DAVE Strong Buy
- TLX Strong Buy
- Analyst Count
- DAVE 6
- TLX 4
- Target Price
- DAVE $265.50
- TLX $21.00
- AVG Volume (30 Days)
- DAVE 388.4K
- TLX 118.4K
- Earning Date
- DAVE 11-04-2025
- TLX 01-01-0001
- Dividend Yield
- DAVE N/A
- TLX N/A
- EPS Growth
- DAVE 70.95
- TLX N/A
- EPS
- DAVE 3.84
- TLX 0.04
- Revenue
- DAVE $433,065,000.00
- TLX $664,225,558.00
- Revenue This Year
- DAVE $50.28
- TLX N/A
- Revenue Next Year
- DAVE $15.34
- TLX N/A
- P/E Ratio
- DAVE $64.70
- TLX $335.52
- Revenue Growth
- DAVE 47.97
- TLX 55.35
- 52 Week Low
- DAVE $37.44
- TLX $8.93
- 52 Week High
- DAVE $286.45
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- DAVE 65.95
- TLX 55.71
- Support Level
- DAVE $208.60
- TLX $10.72
- Resistance Level
- DAVE $224.68
- TLX $11.00
- Average True Range (ATR)
- DAVE 15.01
- TLX 0.28
- MACD
- DAVE 4.28
- TLX 0.10
- Stochastic Oscillator
- DAVE 92.59
- TLX 73.12
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.